Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990–2019: A DALY-based analysis of the Global Burden of Disease 2019 study

Background/Aims Global distribution of dominant liver cancer aetiologies has significantly changed over the past decades. This study analyzed the updated temporal trends of liver cancer aetiologies and sociodemographic status in 204 countries and territories from 1990 to 2019. Methods The Global Burden of Disease 2019 report was used for statistical analysis. In addition, we performed stratification analysis to five quintiles using sociodemographic index and 21 geographic regions. Results The crude numbers of liver cancer disease-adjusted life years (DALYs) and deaths significantly increased during the study period (DALYs; 11,278,630 in 1990 and 12,528,422 in 2019, deaths; 365,215 in 1990 and 484,577 in 2019). However, the Age-standardized DALY and mortality rates decreased. Hepatitis B virus (HBV) remains the leading cause of liver cancer DALYs and mortality, followed by hepatitis C virus (HCV), alcohol consumption, and non-alcoholic steatohepatitis/non-alcoholic fatty liver disease (NASH/NAFLD). Although Age-standardized DALY and mortality rates of liver cancer due to HBV and HCV have decreased, the rates due to alcohol consumption and NASH/NAFLD have increased. In 2019, the population of the East Asia region had the highest Age-standardized DALY and mortality rates, followed by high-income Asia-Pacific and Central Asia populations. Although East Asia and high-income Asia-Pacific regions showed a decrease during the study period, Age-standardized DALY rates increased in Central Asia. High-income North American and Australasian populations also showed a significant increase in Age-standardized DALY. Conclusions Liver cancer remains an ongoing global threat. The burden of liver cancer associated with alcohol consumption and NASH/NAFLD is markedly increasing and projected to continuously increase.

[1]  M. Nierengarten Annual report to the nation on the status of cancer , 2022, Cancer.

[2]  Min Ji Koo,et al.  PRISMA 2020 statement and guidelines for systematic review and meta-analysis articles, and their underlying mathematics: Life Cycle Committee Recommendations , 2022, Life Cycle.

[3]  Hwa Young Choi,et al.  A cost-effectiveness study of universal screening for hepatitis C virus infection in South Korea: A societal perspective , 2021, Clinical and molecular hepatology.

[4]  J. Dufour,et al.  Prevention of NAFLD-associated HCC: role of lifestyle and chemoprevention. , 2021, Journal of hepatology.

[5]  Samiullah Malik,et al.  Epigenetic Mechanisms Involved in HCV-Induced Hepatocellular Carcinoma (HCC) , 2021, Frontiers in Oncology.

[6]  I. Soerjomataram,et al.  Global burden of cancer in 2020 attributable to alcohol consumption: a population-based study , 2021, The Lancet. Oncology.

[7]  A. Jemal,et al.  Annual Report to the Nation on the Status of Cancer, Part 1: National Cancer Statistics , 2021, Journal of the National Cancer Institute.

[8]  Chengbo Yu,et al.  Disease burden of liver cancer attributable to specific etiologies in China from 1990 to 2019: An age-period-cohort analysis , 2021, Science progress.

[9]  S. Ahn,et al.  Screening, confirmation, and treatment rates of hepatitis C virus infection in a tertiary academic medical center in South Korea , 2021, Journal of gastroenterology and hepatology.

[10]  P. Kwo,et al.  Hepatitis C and Hepatocellular Cancer: To Treat or Not to Treat , 2021, Clinical liver disease.

[11]  Wen-Qiang He,et al.  The impact of universal hepatitis B vaccine on the trend of liver cancer from the Global Burden of Disease Study 2017 , 2021, Liver international : official journal of the International Association for the Study of the Liver.

[12]  Hyun Ja Kim,et al.  Trends in Alcohol Consumption for Korean Adults from 1998 to 2018: Korea National Health and Nutritional Examination Survey , 2021, Nutrients.

[13]  H. El‐Serag,et al.  Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention , 2020, Nature Reviews Gastroenterology & Hepatology.

[14]  Li Jin,et al.  Global trend of aetiology-based primary liver cancer incidence from 1990 to 2030: a modelling study. , 2020, International journal of epidemiology.

[15]  Ming‐Lung Yu,et al.  Scaling up the in-hospital hepatitis C virus care cascade in Taiwan , 2020, Clinical and molecular hepatology.

[16]  N. Nishida Metabolic disease as a risk of hepatocellular carcinoma , 2020, Clinical and molecular hepatology.

[17]  P. Kwo,et al.  Current and future strategies for the treatment of chronic hepatitis C , 2020, Clinical and molecular hepatology.

[18]  S. Yoon,et al.  Obesity and the risk of primary liver cancer: A systematic review and meta-analysis , 2020, Clinical and molecular hepatology.

[19]  Eun Sug Park,et al.  Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 , 2020, Lancet.

[20]  Longfei Lin,et al.  The Burden and Trends of Primary Liver Cancer Caused by Specific Etiologies from 1990 to 2017 at the Global, Regional, National, Age, and Sex Level Results from the Global Burden of Disease Study 2017 , 2020, Liver Cancer.

[21]  R. Loomba,et al.  Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH , 2020, Clinical and molecular hepatology.

[22]  C. Graham The Current Status of US and Global Access to Direct‐Acting Antiviral Regimens for Hepatitis C Virus Infection , 2020, Clinical liver disease.

[23]  A. Hill,et al.  Price of a hepatitis C cure: Cost of production and current prices for direct-acting antivirals in 50 countries , 2020, Journal of virus eradication.

[24]  A. Chowdhury,et al.  Epidemiology of non-alcoholic and alcoholic fatty liver diseases. , 2020, Translational gastroenterology and hepatology.

[25]  Z. Younossi,et al.  Nonalcoholic Fatty Liver Disease and Alcoholic Liver Disease are Major Drivers of Liver Mortality in the United States , 2020, Hepatology communications.

[26]  Z. Butt,et al.  The impact of SVR from direct‐acting antiviral‐ and interferon‐based treatments for HCV on hepatocellular carcinoma risk , 2020, Journal of viral hepatitis.

[27]  F. Villarreal,et al.  Sex related differences in the pathogenesis of organ fibrosis. , 2020, Translational research : the journal of laboratory and clinical medicine.

[28]  Z. Younossi,et al.  Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD , 2020, Hepatology.

[29]  P. Lampertico,et al.  Epidemiology and surveillance for hepatocellular carcinoma: New trends. , 2020, Journal of hepatology.

[30]  M. Kumar,et al.  Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission , 2019, The Lancet Gastroenterology & Hepatology.

[31]  D. J. Kim,et al.  Trends in the prevalence of chronic liver disease in the Korean adult population, 1998–2017 , 2019, Clinical and molecular hepatology.

[32]  T. H. Nguyen,et al.  The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2019, The lancet. Gastroenterology & hepatology.

[33]  A. Cox,et al.  Challenges and Promise of a Hepatitis C Virus Vaccine. , 2019, Cold Spring Harbor perspectives in medicine.

[34]  A. Xu,et al.  Recent advances in the molecular mechanism of sex disparity in hepatocellular carcinoma. , 2019, Oncology letters.

[35]  T. Asselah,et al.  Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study , 2019, The Lancet.

[36]  M. Ho,et al.  Androgen Receptor Enhances Hepatic Telomerase Reverse Transcriptase Gene Transcription After Hepatitis B Virus Integration or Point Mutation in Promoter Region , 2019, Hepatology.

[37]  P. Belperio,et al.  Impact of Sustained Virologic Response with Direct‐Acting Antiviral Treatment on Mortality in Patients with Advanced Liver Disease , 2019, Hepatology.

[38]  A. Dimarino,et al.  Persistent risk for new, subsequent new and recurrent hepatocellular carcinoma despite successful anti-hepatitis B virus therapy and tumor ablation: The need for hepatitis B virus cure , 2019, World journal of hepatology.

[39]  Eleanor Barnes,et al.  Approaches, Progress, and Challenges to Hepatitis C Vaccine Development , 2019, Gastroenterology.

[40]  Longfei Lin,et al.  The Burden and Trends of Primary Liver Cancer Caused by Specific Etiologies from 1990 to 2017 at the Global, Regional, National, Age, and Gender Level Results from the Global Burden of Disease Study 2017 , 2019, SSRN Electronic Journal.

[41]  Austin Carter,et al.  Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories , 2018, The Lancet.

[42]  S. Anticoli,et al.  Sex-Dependent Outcome of Hepatitis B and C Viruses Infections: Synergy of Sex Hormones and Immune Responses? , 2018, Front. Immunol..

[43]  M. Manns,et al.  Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. , 2018, Journal of hepatology.

[44]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[45]  T. Tseng,et al.  HCC risk in patients with HBV‐related cirrhosis receiving nucleos(t)ide analogues therapy: Is HCC prevented or delayed? , 2018, Hepatology.

[46]  A. Singal,et al.  Hepatitis C Virus and Hepatocellular Carcinoma: A Narrative Review , 2017, Journal of clinical and translational hepatology.

[47]  Rohit Loomba,et al.  Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease , 2017, Hepatology.

[48]  L. Henry,et al.  Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention , 2018, Nature Reviews Gastroenterology & Hepatology.

[49]  F. Bray,et al.  Projections of primary liver cancer to 2030 in 30 countries worldwide , 2018, Hepatology.

[50]  G. Dusheiko,et al.  Hepatitis B in sub-Saharan Africa: strategies to achieve the 2030 elimination targets. , 2017, The lancet. Gastroenterology & hepatology.

[51]  Namkug Kim,et al.  Increasing burden of liver cancer despite extensive use of antiviral agents in a hepatitis B virus‐endemic population , 2017, Hepatology.

[52]  Alan D. Lopez,et al.  The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level , 2017, JAMA oncology.

[53]  S. Asch,et al.  Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. , 2017, Gastroenterology.

[54]  A. Aghemo,et al.  Direct-acting antivirals: the endgame for hepatitis C? , 2017, Current opinion in virology.

[55]  A. Dimarino,et al.  Persistent risk for hepatocellular carcinoma after more than a decade of successful hepatitis B virus suppression. , 2017, Minerva gastroenterologica e dietologica.

[56]  G. Ioannou,et al.  HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. , 2017, Journal of hepatology.

[57]  C. Friedenreich,et al.  Cancer incidence attributable to alcohol consumption in Alberta in 2012. , 2016, CMAJ open.

[58]  L. Henry,et al.  Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.

[59]  Jie Chen,et al.  Menopausal hormone therapy use and risk of primary liver cancer in the clinical practice research datalink , 2016, International journal of cancer.

[60]  Ahmedin Jemal,et al.  Annual Report to the Nation on the Status of Cancer, 1975‐2012, featuring the increasing incidence of liver cancer , 2016, Cancer.

[61]  B. Cowie,et al.  Hepatitis B virus epidemiology. , 2015, Cold Spring Harbor perspectives in medicine.

[62]  M. Noureddin,et al.  Nonalcoholic Fatty liver disease, diabetes, obesity, and hepatocellular carcinoma. , 2015, Clinics in liver disease.

[63]  A. Jemal,et al.  Annual Report to the Nation on the status of cancer, 1975‐2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer , 2014, Cancer.

[64]  S. Park KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease , 2013, Clinical and molecular hepatology.

[65]  K. McGlynn,et al.  The global epidemiology of hepatocellular carcinoma: present and future. , 2011, Clinics in liver disease.

[66]  M. Weltman,et al.  Epidemiology of hepatitis C virus infection in Australia , 1993, Gastroenterologia Japonica.

[67]  T. Morgan,et al.  Alcohol and hepatocellular carcinoma. , 2004, Gastroenterology.

[68]  D. Woodfield Hepatocellular carcinoma. , 1986, The New Zealand medical journal.